The Journal of Bone and Joint Surgery (American). 2006;88:1163.
© 2006 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Related articles in JBJS
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lotke, P. A.
Right arrow Articles by Thornhill, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotke, P. A.
Right arrow Articles by Thornhill, T. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Letter to the Editor

Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

Paul A. Lotke, MD, John J. Callaghan, MD, Lawrence D. Dorr, MD, Gerard H. Engh, MD, Arlen D. Hanssen, MD, William L. Healy, MD, Paul F. Lachiewicz, MD, Jess H. Lonner, MD, Charles Nelson, MD, Chitranjan S. Ranawat, MD, Merrill A. Ritter, MD, Eduardo A. Salvati, MD, Thomas P. Sculco, MD and Thomas S. Thornhill, MD

Corresponding author:
Paul A. Lotke, MD
510 Darby Road
Havertown, PA 19083
paul.lotke@uphs.upenn.edu

The first 20% of the full text of this article appears below.

To The Editor:

After reading the article by Colwell et al., "Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty" (2005;87:2169-77), we are concerned that the facts presented by the authors do not appear to justify their conclusions and that some important parameters of patient evaluations are lacking.

In this report, the authors note that 0.3% of the patients in the ximelagatran group died from a cause in which pulmonary embolism could not be ruled out whereas there were no deaths from pulmonary embolism in the warfarin group. This incidence is relatively . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related articles in JBJS:

Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
Clifford W. Colwell, Jr., Scott D. Berkowitz, Jay R. Lieberman, Philip C. Comp, Jeffrey S. Ginsberg, Guy Paiement, Jennifer McElhattan, Anne W. Roth, Charles W. Francis, and The EXULT B Study Group
JBJS 2005 87: 2169-2177. [Abstract] [Full Text]